Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary.

Oncologist · 2022 · PMC8842368 · PMID 35305098

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

did not reach statistical significanceP = .13not close (p > 0.1)

Median overall survival was longer among patients treated with molecularly guided therapy ( n = 17) compared with patients treated with standard options ( n = 78), although this observation did not reach statistical significance (23.6 months vs 14.7 months; hazard ratio for death, 0.568; 95% confidence interval [CI], 0.268 to 1.205; P = .13; Figure 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.